DexCom, Inc. (NASDAQ:DXCM) Shares Acquired by Aquila Investment Management LLC

Aquila Investment Management LLC increased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 50.0% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 42,000 shares of the medical device company’s stock after acquiring an additional 14,000 shares during the period. DexCom comprises about 3.1% of Aquila Investment Management LLC’s portfolio, making the stock its 9th biggest position. Aquila Investment Management LLC’s holdings in DexCom were worth $2,816,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of DXCM. Ballentine Partners LLC increased its stake in DexCom by 11.8% during the 1st quarter. Ballentine Partners LLC now owns 2,517 shares of the medical device company’s stock valued at $349,000 after purchasing an additional 266 shares in the last quarter. Global Assets Advisory LLC bought a new stake in DexCom during the 1st quarter valued at $2,296,000. Harbor Investment Advisory LLC lifted its holdings in DexCom by 13.1% during the 1st quarter. Harbor Investment Advisory LLC now owns 864 shares of the medical device company’s stock worth $120,000 after purchasing an additional 100 shares in the last quarter. Riverview Trust Co bought a new stake in DexCom during the 1st quarter worth approximately $32,000. Finally, Sound Income Strategies LLC boosted its position in shares of DexCom by 41.7% during the 1st quarter. Sound Income Strategies LLC now owns 340 shares of the medical device company’s stock valued at $47,000 after acquiring an additional 100 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $73.08 on Wednesday. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a market cap of $29.06 billion, a price-to-earnings ratio of 47.15, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. The stock’s 50-day moving average is $70.03 and its two-hundred day moving average is $99.06.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.04. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The business’s quarterly revenue was up 15.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.34 EPS. Analysts forecast that DexCom, Inc. will post 1.69 EPS for the current fiscal year.

Insider Transactions at DexCom

In related news, EVP Michael Jon Brown sold 652 shares of DexCom stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total value of $45,346.60. Following the sale, the executive vice president now directly owns 66,249 shares in the company, valued at $4,607,617.95. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael Jon Brown sold 652 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total transaction of $45,346.60. Following the sale, the executive vice president now directly owns 66,249 shares of the company’s stock, valued at approximately $4,607,617.95. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,824 shares of company stock worth $126,390. Company insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

DXCM has been the topic of several recent analyst reports. Robert W. Baird raised their target price on DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, August 5th. Oppenheimer lowered their price target on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, July 26th. BTIG Research dropped their target price on shares of DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a report on Friday, July 26th. Stifel Nicolaus raised their price target on DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday, August 23rd. Finally, Barclays dropped their price objective on DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research note on Monday, July 29th. Seven investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $110.73.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.